Emerging Applications of CRISPR Technology in Biomedical Research and Therapeutics

Lukas Martin Schneider
Institute for Pharmaceutical Technology and Nanomedicine, Ludwig Maximilian University of Munich, Germany

* Corresponding Author: **Lukas Martin Schneider**

Article Info

Volume: 01
Issue: 06
Received: 06-09-2025
Accepted: 04-10-2025
Published: 02-11-2025
Page No: 01-05

Abstract
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) have fundamentally transformed the landscape of molecular biology and biomedicine. Since its adaptation as a programmable genome editing tool in 2012, CRISPR technology has expanded into a diverse ecosystem of platforms—including base editors, prime editors, and RNA-targeting systems—each offering distinct advantages in editing efficiency, target specificity, and therapeutic applicability. This review provides a comprehensive overview of contemporary CRISPR platforms, their mechanistic underpinnings, and their translation into clinical applications spanning monogenic blood disorders, ocular diseases, cardiac amyloidosis, and oncology. We further examine critical metrics—including on-target editing efficiency, off-target cleavage rates, and therapeutic outcomes—and address the ethical, regulatory, and safety considerations that accompany the clinical deployment of these transformative technologies. The approval of exagamglogene autotemcel (exa-cel) by the FDA in 2023 marks a pivotal milestone, heralding a new era of CRISPR-based medicine.

Keywords: CRISPR-Cas9, Genome editing, Base editing, Prime editing, RNA-targeting systems, Gene therapy, Therapeutic applications

1. Introduction

The discovery of the CRISPR-Cas9 system as an adaptive immune mechanism in prokaryotes, and its subsequent engineering as a precise genome editing tool, represents one of the most consequential developments in the history of molecular biology [1, 2]. The 2020 Nobel Prize in Chemistry, awarded to Jennifer Doudna and Emmanuelle Charpentier, underscored the transformative impact of this technology on science and medicine. Within a decade of its initial characterization, CRISPR-based tools have progressed from proof-of-concept experiments in cultured cells to approved therapeutic interventions in humans [3, 4].

Genome editing refers to the deliberate introduction of targeted modifications—including deletions, insertions, or substitutions—into the genome of a living organism. The CRISPR-Cas9 platform achieves this through a guide RNA (gRNA) that directs the Cas9 endonuclease to a complementary DNA sequence, where it induces a double-strand break (DSB) [1]. Cellular DNA repair pathways then resolve the break either through error-prone non-homologous end joining (NHEJ), resulting in insertions or deletions (indels), or through homology-directed repair (HDR), enabling precise sequence correction when a donor template is provided [17].

The versatility of CRISPR technology extends well beyond simple gene knockouts. Second- and third-generation tools including base editors, prime editors, and CRISPRa/i systems allow for single-nucleotide correction, targeted insertion of therapeutic sequences, and programmable transcriptional regulation—all without obligatory DSB formation [5, 6, 16]. This review synthesizes current knowledge on CRISPR platforms, their biomedical applications, and the ethical landscape governing their clinical translation.

2. CRISPR Technology Platforms

The CRISPR toolbox has expanded dramatically since the original SpCas9 system was described. Table 1 provides a comparative summary of major CRISPR platforms currently employed in research and therapeutic development.

Table 1: Comparative Overview of Major CRISPR-Cas Systems

System	Nuclease	PAM Req.	Editing Efficiency	Specificity	Primary Use
CRISPR-Cas9	Cas9 (SpCas9)	NGG	60–85%	High	Gene KO, HDR
CRISPR-Cas12a	Cpf1	TTTV	55–80%	Very High	Multiplex editing
CRISPR-Cas13	Cas13d	None (RNA)	70–90%	High	RNA targeting
Base Editing (ABE)	Cas9-deaminase	NGG	40–75%	Very High	A·T→G·C correction
Base Editing (CBE)	Cas9-deaminase	NGG	30–70%	High	C·G→T·A correction
Prime Editing	Cas9-RT fusion	NGG	10–50%	Very High	Precise insertions
CRISPRa/i	dCas9-activator	NGG	N/A	High	Gene regulation

KO = knockout; HDR = homology-directed repair; PAM = protospacer adjacent motif; RT = reverse transcriptase; dCas9 = catalytically dead Cas9; ABE = adenine base editor; CBE = cytosine base editor.

The canonical SpCas9 nuclease, guided by a single-guide RNA (sgRNA), remains the most widely deployed editing tool, offering robust efficiency for gene disruption and, with donor templates, for HDR-mediated correction [17]. Cas12a (formerly Cpf1) processes its own CRISPR RNA, generates staggered cuts, and recognizes T-rich PAM sequences, providing a complementary targeting range [8]. Cas13 variants uniquely target RNA rather than DNA, offering applications in transcriptome modulation, viral RNA degradation, and RNA diagnostics [7].

Base editors—cytosine base editors (CBEs) and adenine base editors (ABEs)—fuse catalytically impaired Cas9 variants to deaminase enzymes, enabling C·G-to-T·A or A·T-to-G·C transitions without DSB induction, with very high precision [5]. Prime editing employs a Cas9 nickase fused to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA) that encodes the desired edit, enabling all twelve types of point mutations as well as small insertions and deletions [6]. CRISPRa and CRISPRi systems use transcriptional activators or repressors fused to catalytically dead Cas9 (dCas9) to modulate gene expression without altering the DNA sequence [15].

3. Molecular Mechanism of CRISPR-Cas9 Genome Editing

Understanding the mechanistic basis of CRISPR-Cas9 function is essential for optimizing editing outcomes and mitigating off-target effects. Figure 1 illustrates the sequential steps of the editing process.



Fig 1: Stepwise Mechanism of CRISPR-Cas9-Mediated Genome Editing

Editing efficiency is governed by multiple factors: sgRNA secondary structure, GC content, proximity to the PAM, chromatin accessibility, and the proliferative state of target cells. High-fidelity Cas9 variants such as eSpCas9, HiFi Cas9, and HypaCas9 have been engineered to reduce non-specific DNA binding and lower off-target cleavage rates below detection thresholds in whole-genome sequencing studies [20,21,22]. Delivery modalities—including viral vectors (AAV, lentivirus), lipid nanoparticles (LNPs), and ribonucleoprotein (RNP) electroporation—critically influence both on-target efficiency and immunogenicity [33, 34, 35].

4. Biomedical Applications and Therapeutic Interventions

CRISPR technology has achieved remarkable clinical translation across multiple disease domains. Table 2 summarizes key therapeutic programs organized by indication, target, tool, and clinical stage.

Table 2: Selected CRISPR Therapeutic Programs in Clinical Development or Approved Use

Disease	Target Gene/Locus	CRISPR Tool	Stage	Key Outcome
Sickle Cell Disease	BCL11A / HBG1/2	Cas9 (exa-cel)	FDA Approved (2023)	~95% HbF induction
β-Thalassemia	BCL11A enhancer	Cas9 (exa-cel)	FDA Approved (2023)	Transfusion independence
Transthyretin Amyloidosis	TTR gene	Cas9 LNP (NTLA-2001)	Phase I/II	≥93% TTR reduction
Duchenne MD	Exon 51 skip	Cas9 / Base editing	Phase I/II	Dystrophin restoration
Leber Congenital Amaurosis	CEP290 IVS26	Cas9 *in vivo* (EDIT-101)	Phase I/II	Vision improvement
HIV-1 Infection	CCR5 / HIV provirus	Cas9 ex vivo	Phase I	Viral reservoir reduction
Acute Lymphoblastic Leukemia	CD7 / TRAC loci	Cas9 CAR-T (UCART)	Phase I	CR in relapsed pts
Hereditary Angioedema	KLKB1 / F12	siRNA + Cas9	Phase I/II	Attack frequency ↓80%
Hypercholesterolemia	PCSK9	Base editing (VERVE)	Phase I	LDL-C ↓55%
Chronic Granulomatous Dis.	CYBB (gp91phox)	Cas9 HSC editing	Phase I	Neutrophil function restored

CR = complete remission; HDR = homology-directed repair; HSC = hematopoietic stem cell; HbF = fetal hemoglobin; LDL-C = low-density lipoprotein cholesterol; LNP = lipid nanoparticle; KO = knockout; CAR-T = chimeric antigen receptor T-cell; UCART = universal CAR-T.

4.1. Hematological Disorders

The most advanced and clinically validated applications of CRISPR technology reside in hematology. Exagamglogene autotemcel (exa-cel, Casgevy), a CRISPR-Cas9-based therapy, received regulatory approval from the FDA and EMA in late 2023 for the treatment of sickle cell disease (SCD) and transfusion-dependent β-thalassemia [9]. The strategy involves ex vivo editing of autologous hematopoietic stem and progenitor cells (HSPCs) to disrupt the BCL11A erythroid enhancer, thereby reactivating fetal hemoglobin (HbF) expression. In pivotal trials, 93.5% of SCD patients were free of vaso-occlusive crises at 12 months, and 89.4% of β-thalassemia patients achieved transfusion independence [9].

4.2. Genetic and Metabolic Diseases

Transthyretin amyloidosis (ATTR), caused by misfolded TTR protein deposition in the heart and peripheral nerves, represents an ideal target for *in vivo* CRISPR editing. The NTLA-2001 program employs Cas9 mRNA and sgRNA encapsulated in lipid nanoparticles delivered intravenously to hepatocytes, achieving sustained reductions in serum TTR of over 90% after a single dose [10]. Similar approaches targeting PCSK9 for familial hypercholesterolemia and KLKB1/F12 for hereditary angioedema are in early clinical trials, with base editing emerging as the preferred approach for liver-targeted applications [38].

4.3. Oncology and Immunotherapy

CRISPR has significantly advanced cancer immunotherapy by enabling the generation of universal allogeneic CAR-T cells. Multiplex editing at the TRAC (T-cell receptor alpha constant) and B2M loci eliminates endogenous TCR expression and MHC class I presentation, reducing the risk of graft-versus-host disease and immune rejection [39]. In a landmark case series, CRISPR-edited universal CAR-T cells induced complete remissions in pediatric patients with relapsed/refractory T-cell leukemia [14]. Additionally, CRISPR disruption of immune checkpoint genes such as PD-1 in tumor-infiltrating lymphocytes has shown early promise in enhancing anti-tumor responses [27].

4.4. Ophthalmology and Neurological Disorders

In vivo CRISPR editing within the eye represents a particularly promising avenue due to the organ's relative immune privilege and accessibility. EDIT-101, targeting a splice site mutation in the CEP290 gene responsible for Leber congenital amaurosis type 10 (LCA10), demonstrated improvements in visual sensitivity and acuity in a subset of treated patients following subretinal injection [13]. For Duchenne muscular dystrophy (DMD), exon-skipping strategies using Cas9 have restored partial dystrophin expression in patient-derived myoblasts and in animal models, with human trials underway [12].

5. Critical Metrics in CRISPR Therapeutics

Three parameters are central to evaluating clinical CRISPR programs. Editing efficiency—the percentage of alleles modified in target cells—must be sufficiently high to achieve therapeutic benefit while avoiding the risks of partial correction. In HSC editing, allele modification rates above 60–70% are generally considered clinically meaningful [9, 11]. Off-target specificity, assessed by whole-genome sequencing, GUIDE-Seq, DISCOVER-Seq, and related methods, has emerged as a primary safety endpoint [30]. High-fidelity Cas9 variants and optimized RNP delivery have substantially reduced off-target signatures to sub-detectable levels in most current clinical programs [20, 22]. Therapeutic outcomes, including durable engraftment of edited cells, biomarker normalization, and patient-reported endpoints, form the ultimate standard of clinical efficacy [9, 10].

6. Ethical Considerations

The deployment of CRISPR in clinical settings raises profound ethical questions that extend beyond technical feasibility. The 2018 announcement by He Jiankui of the

birth of gene-edited human embryos, in which CCR5 was disrupted to confer putative HIV resistance, provoked international condemnation and catalyzed regulatory responses worldwide [26]. The consensus among bioethicists, clinicians, and regulatory bodies is that heritable germline genome editing—modifications that would be transmitted to future generations—is premature and ethically impermissible in the absence of robust safety data, societal consensus, and appropriate regulatory frameworks [24, 25].

In contrast, somatic cell gene editing, which affects only the treated individual, has a more established ethical foundation analogous to conventional gene therapy. Nonetheless, questions of equitable access, informed consent in pediatric populations, the threshold of severity for permissible intervention, and the long-term monitoring of edited patients require ongoing deliberation [43]. Regulatory agencies including the FDA, EMA, and WHO have developed evolving frameworks requiring preclinical genotoxicity studies, long-term follow-up, and transparent reporting of adverse events. The principle of proportionality—that the risks of editing must be commensurate with the severity of the target disease—remains central to ethical review.

Enhancement applications—using CRISPR to augment traits such as intelligence, athletic performance, or longevity in otherwise healthy individuals—remain broadly proscribed and ethically contentious. The distinction between treatment and enhancement, while philosophically complex, provides an important heuristic for regulatory boundaries [24, 43].

7. Conclusion and Future Perspectives

CRISPR technology has traversed the journey from bacterial immune system to approved human medicine in less than a decade, a pace unprecedented in the history of molecular therapeutics. The approval of exa-cel in 2023 validates the translational potential of ex vivo CRISPR editing for monogenic diseases, while *in vivo* programs for liver-targeted disorders suggest the platform's reach will expand substantially. Next-generation tools—prime editors capable of all point mutations, base editors with minimal bystander activity, Cas13-based RNA medicines, and epigenome editors—promise to extend the therapeutic addressable space to conditions previously beyond reach [6, 16]. Advances in delivery, including organ-specific LNP formulations and engineered AAV capsids with reduced immunogenicity, will be critical to realizing this potential [33]. As the field matures, sustained commitment to rigorous safety assessment, ethical governance, and equitable access will be as important as continued scientific innovation in ensuring that CRISPR's promise is realized for patients worldwide.

References

1. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2012;346(6213):1258096.
2. Jinek M, Chylinski K, Fonfara I, *et al*. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-821.
3. Cong L, Ran FA, Cox D, *et al*. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-823.
4. Mali P, Yang L, Esvelt KM, *et al*. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823-826.
5. Komor AC, Kim YB, Packer MS, *et al*. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420-424.
6. Anzalone AV, Randolph PB, Davis JR, *et al*. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149-157.
7. Abudayyeh OO, Gootenberg JS, Essletzbichler P, *et al*. RNA targeting with CRISPR-Cas13. Nature. 2017;550(7675):280-284.
8. Zetsche B, Gootenberg JS, Abudayyeh OO, *et al*. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163(3):759-771.
9. Frangoul H, Altshuler D, Cappellini MD, *et al*. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252-260.
10. Gillmore JD, Gane E, Taubel J, *et al*. CRISPR-Cas9 *in vivo* gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493-502.
11. Zeng J, Wu Y, Ren C, *et al*. Therapeutic base editing of human hematopoietic stem cells. Nat Med. 2020;26(4):535-541.
12. Amoasii L, Hildyard JCW, Li H, *et al*. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science. 2018;362(6410):86-91.
13. Maeder ML, Stefanidakis M, Wilson CJ, *et al*. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019;25(2):229-233.
14. Xu L, Wang J, Liu Y, *et al*. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med. 2019;381(13):1240-1247.
15. Liu XS, Wu H, Ji X, *et al*. Editing DNA methylation in the mammalian genome. Cell. 2016;167(1):233-247.
16. Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020;38(7):824-844.
17. Ran FA, Hsu PD, Wright J, *et al*. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281-2308.
18. Hsu PD, Scott DA, Weinstein JA, *et al*. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013;31(9):827-832.
19. Fu Y, Foden JA, Khayter C, *et al*. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822-826.
20. Kleinstiver BP, Pattanayak V, Prew MS, *et al*. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490-495.
21. Chen JS, Dagdas YS, Kleinstiver BP, *et al*. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. Nature. 2017;550(7676):407-410.
22. Casini A, Olivieri M, Petris G, *et al*. A highly specific SpCas9 variant is identified by *in vivo* screening in yeast. Nat Biotechnol. 2018;36(3):265-271.
23. Liang P, Xu Y, Zhang X, *et al*. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015;6(5):363-372.
24. Baltimore D, Berg P, Botchan M, *et al*. A prudent path forward for genomic engineering and germline gene modification. Science. 2015;348(6230):36-38.
25. Lander ES, Baylis F, Zhang F, *et al*. Adopt a moratorium on heritable genome editing. Nature.

2019;567(7747):165-168.
26. Greely HT. CRISPR'd babies: human germline genome editing in the 'He Jiankui affair'. J Law Biosci. 2019;6(1):111-183.
27. Porteus MH. A new class of medicines through DNA editing. N Engl J Med. 2019;380(10):947-959.
28. Carroll D. Genome editing: past, present, and future. Yale J Biol Med. 2017;90(4):653-659.
29. Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765-771.
30. Wienert B, Wyman SK, Richardson CD, *et al*. Unbiased detection of CRISPR off-targets *in vivo* using DISCOVER-Seq. Science. 2019;364(6437):286-289.
31. Sharma G, Sharma AR, Bhattacharya M, *et al*. CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol Ther. 2021;29(2):571-586.
32. Gupta D, Bhatt S, Gupta M, *et al*. Future of acute myeloid leukemia: CRISPR/Cas9 gene editing. J Exp Clin Cancer Res. 2019;38(1):1-22.
33. Glass Z, Lee M, Li Y, Xu Q. Engineering the delivery system for CRISPR-based genome editing. Trends Biotechnol. 2018;36(2):173-185.
34. Wang HX, Li M, Lee CM, *et al*. CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem Rev. 2017;117(15):9874-9906.
35. Li L, Hu S, Chen X. Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities. Biomaterials. 2018;171:207-218.
36. Charlesworth CT, Deshpande PS, Dever DP, *et al*. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249-254.
37. Crudele JM, Chamberlain JS. Cas9 immunity creates challenges for CRISPR gene editing therapy. Nat Commun. 2018;9(1):3497.
38. Ihry RJ, Worringer KA, Salick MR, *et al*. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24(7):939-946.
39. Eyquem J, Mansilla-Soto J, Giavridis T, *et al*. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-117.
40. Ribeiro LF, Ribeiro LFC, Barreto MQ, Ward RJ. Protein engineering strategies to expand CRISPR-Cas9 applications. Int J Genomics. 2018;2018:1652567.
41. Yin H, Xue W, Chen S, *et al*. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32(6):551-553.
42. Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351-360.
43. Rodriguez E. Ethical issues in genome editing using CRISPR/Cas9 system. J Clin Res Bioeth. 2016;7(2):266.

How to Cite This Article
Schneider LM. Emerging applications of CRISPR technology in biomedical research and therapeutics. Int J Biol Biomed Res. 2025;1(6):1–5.